{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:39:12Z","timestamp":1762324752058,"version":"build-2065373602"},"reference-count":96,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>In recent years, much progress has been made in the field of antithrombotic drugs in acute coronary syndrome (ACS) treatment, as reflected by the introduction of the more potent P2Y12-inhibitors prasugrel and ticagrelor, and novel forms of concomitant anticoagulation, such as fondaparinux and bivalirudin. However, despite substantial improvements in contemporary ACS treatment, there remains residual ischemic risk in this group and hence the need for even more effective antithrombotic drugs, while balancing antithrombotic efficacy against bleeding risk. This review discusses recently introduced and currently developed antiplatelet and anticoagulant drugs in ACS treatment.<\/jats:p>","DOI":"10.3390\/jcm9072059","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T14:29:39Z","timestamp":1593527379000},"page":"2059","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["New Antithrombotic Drugs in Acute Coronary Syndrome"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7431-7586","authenticated-orcid":false,"given":"Bastiaan","family":"Zwart","sequence":"first","affiliation":[{"name":"Department of Cardiology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands"},{"name":"Department of Cardiology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7822-8852","authenticated-orcid":false,"given":"William A. E.","family":"Parker","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield S10 2RX, UK"},{"name":"South Yorkshire Cardiothoracic Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S5 7AU, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6677-6229","authenticated-orcid":false,"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield S10 2RX, UK"},{"name":"South Yorkshire Cardiothoracic Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S5 7AU, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJM199604253341710","article-title":"Platelets and coronary artery disease","volume":"334","author":"Handin","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"EPIC Investigators (1994). Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med., 330, 956\u2013961.","DOI":"10.1056\/NEJM199404073301402"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Restore Investigators (1997). Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation, 96, 1445\u20131453.","DOI":"10.1161\/01.CIR.96.5.1445"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Neumann","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jacc.2017.08.037","article-title":"Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis","volume":"70","author":"Patrono","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_11","unstructured":"Ibanez, B., James, S., Agewall, S., Antunes, M.J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A.L.P., Crea, F., Goudevenos, J.A., and Halvorsen, S. (2017). 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","article-title":"Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease","volume":"29","author":"Wallentin","year":"2008","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1160\/TH16-02-0102","article-title":"Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction","volume":"116","author":"Thomas","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/eurheartj\/ehv547","article-title":"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: The randomized, double-blind, placebo-controlled IMPRESSION trial","volume":"37","author":"Kubica","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Parodi, G., Bellandi, B., Xanthopoulou, I., Capranzano, P., Capodanno, D., Valenti, R., Stavrou, K., Migliorini, A., Antoniucci, D., and Tamburino, C. (2015). Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ. Cardiovasc. Interv., 8.","DOI":"10.1161\/CIRCINTERVENTIONS.114.001593"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1160\/TH15-12-0944","article-title":"P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study","volume":"116","author":"Silvain","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/09537104.2019.1665642","article-title":"Use of glycoprotein IIb\/IIIa antagonists to prevent stent thrombosis in morphine-treated patients with ST-elevation myocardial infarction","volume":"31","author":"Zwart","year":"2020","journal-title":"Platelets"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/09537104.2016.1218453","article-title":"Safety and efficacy of IIb\/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials","volume":"28","author":"Roule","year":"2017","journal-title":"Platelets"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/14779072.2016.1207528","article-title":"Cangrelor for the management and prevention of arterial thrombosis","volume":"14","author":"Storey","year":"2016","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/j.1538-7836.2011.04419.x","article-title":"Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses","volume":"9","author":"Storey","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-0037-1615596","article-title":"Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes","volume":"85","author":"Storey","year":"2001","journal-title":"Thromb. Haemost."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0091270009344986","article-title":"Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: A direct, parenteral P2Y12 receptor antagonist","volume":"50","author":"Akers","year":"2010","journal-title":"J Clin Pharm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1074248417715004","article-title":"Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives","volume":"23","author":"Alexopoulos","year":"2018","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40256-016-0192-1","article-title":"Optimizing the Use of Cangrelor in the Real World","volume":"17","author":"Qamar","year":"2017","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Gorog, D.A., Price, S., Sibbing, D., Baumbach, A., Capodanno, D., Gigante, B., Halvorsen, S., Huber, K., Lettino, M., and Leonardi, S. (2020). Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: A Joint Position Paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. Cardiovasc. Pharm.","DOI":"10.1093\/ehjcvp\/pvaa009"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Parker, W.A.E., and Storey, R.F. (2020). Novel approaches to P2Y12 inhibition and aspirin dosing. Platelets, 1\u20138.","DOI":"10.1080\/09537104.2020.1714574"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14728214.2020.1729121","article-title":"Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y12 receptor antagonist","volume":"25","author":"Parker","year":"2020","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1016\/j.bmcl.2014.06.070","article-title":"Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y(12) antagonists for inhibition of platelet aggregation","volume":"24","author":"Caroff","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Rey, M., Kramberg, M., Hess, P., Morrison, K., Ernst, R., Haag, F., Weber, E., Clozel, M., Baumann, M., and Caroff, E. (2017). The reversible P2Y12 antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat. Pharm. Res. Perspect., 5.","DOI":"10.1002\/prp2.338"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40261-014-0236-8","article-title":"A new reversible and potent P2Y12 receptor antagonist (ACT-246475): Tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trial","volume":"34","author":"Baldoni","year":"2014","journal-title":"Clin. Drug Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/jcph.1296","article-title":"Clinical Pharmacology of the Reversible and Potent P2Y12 Receptor Antagonist ACT-246475 After Single Subcutaneous Administration in Healthy Male Subjects","volume":"59","author":"Juif","year":"2019","journal-title":"J. Clin. Pharm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/00498254.2019.1646440","article-title":"Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects","volume":"50","author":"Ufer","year":"2020","journal-title":"Xenobiotica"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Storey, R.F., Gurbel, P.A., Ten Berg, J., Bernaud, C., Dangas, G.D., Frenoux, J.-M., Gorog, D.A., Hmissi, A., Kunadian, V., and James, S.K. (2019). Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. Eur. Heart J.","DOI":"10.1093\/eurheartj\/ehz807"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"ehz746.0078","DOI":"10.1093\/eurheartj\/ehz746.0078","article-title":"Inhibition of platelet aggregation after subcutaneous administration of a single-dose of selatogrel, a novel P2Y12 antagonist, in acute myocardial infarction: A randomised open-label phase 2 study","volume":"40","author":"Sinnaeve","year":"2019","journal-title":"Eur Heart J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40169-020-0261-6","article-title":"PI3K inhibitors in thrombosis and cardiovascular disease","volume":"9","author":"Durrant","year":"2020","journal-title":"Clin. Transl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1042\/BJ20100166","article-title":"Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways","volume":"429","author":"Garcia","year":"2010","journal-title":"Biochem. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejphar.2008.03.017","article-title":"Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat","volume":"587","author":"Sturgeon","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1111\/j.1538-7836.2012.04898.x","article-title":"Human target validation of phosphoinositide 3-kinase (PI3K)\u03b2: Effects on platelets and insulin sensitivity, using AZD6482 a novel PI3K\u03b2 inhibitor","volume":"10","author":"Nylander","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1158\/1078-0432.CCR-17-0725","article-title":"A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors","volume":"23","author":"Mateo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_48","unstructured":"Parker, W.A.E., and Storey, R.F. (2018). \u2018Thrombotic Response\u2019 in ESC Textbook of Cardiovascular Medicine, Oxford University Press. [3rd ed.]."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1161\/01.CIR.98.16.1616","article-title":"Differential effects of glycoprotein IIb\/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists","volume":"98","author":"Storey","year":"1998","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2017-03-773614","article-title":"Integrin \u03b1IIb\u03b23 outside-in signaling","volume":"130","author":"Durrant","year":"2017","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nature12613","article-title":"A directional switch of integrin signalling and a new anti-thrombotic strategy","volume":"503","author":"Shen","year":"2013","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/01.RES.0000232317.84122.0c","article-title":"Conformation-specific blockade of the integrin GPIIb\/IIIa: A novel antiplatelet strategy that selectively targets activated platelets","volume":"99","author":"Schwarz","year":"2006","journal-title":"Circ. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1182\/blood-2012-08-449694","article-title":"Delayed targeting of CD39 to activated platelet GPIIb\/IIIa via a single-chain antibody: Breaking the link between antithrombotic potency and bleeding?","volume":"121","author":"Hohmann","year":"2013","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1182\/blood-2004-11-4434","article-title":"GPVI and alpha2beta1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow","volume":"106","author":"Sarratt","year":"2005","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.110.980623","article-title":"Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans","volume":"123","author":"Ungerer","year":"2011","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1055\/s-0039-1692423","article-title":"Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing Elective PCI-Design and Rationale of the Randomized ISAR-PLASTER Trial","volume":"119","author":"Mayer","year":"2019","journal-title":"Thromb. Haemost."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/19420862.2017.1336592","article-title":"Design, development and characterization of ACT017, a humanized Fab that blocks platelet\u2019s glycoprotein VI function without causing bleeding risks","volume":"9","author":"Lebozec","year":"2017","journal-title":"MAbs"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1161\/ATVBAHA.118.312314","article-title":"Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab","volume":"39","author":"Lebozec","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"36984","DOI":"10.1074\/jbc.M003279200","article-title":"The platelet integrin alpha IIbbeta 3 has an endogenous thiol isomerase activity","volume":"275","author":"Robinson","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e89373","DOI":"10.1172\/jci.insight.89373","article-title":"Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation","volume":"2","author":"Stopa","year":"2017","journal-title":"JCI Insight."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Zwicker, J.I., Schlechter, B.L., Stopa, J.D., Liebman, H.A., Aggarwal, A., Puligandla, M., Caughey, T., Bauer, K.A., Kuemmerle, N., and Wong, E. (2019). Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight, 4.","DOI":"10.1172\/jci.insight.125851"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.redox.2017.05.019","article-title":"HPW-RX40 prevents human platelet activation by attenuating cell surface protein disulfide isomerases","volume":"13","author":"Kung","year":"2017","journal-title":"Redox Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3109\/09537104.2014.902924","article-title":"PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact","volume":"26","author":"Judge","year":"2015","journal-title":"Platelets"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood-2014-09-599910","article-title":"Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar","volume":"125","author":"Aisiku","year":"2015","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Wong, P.C., Seiffert, D., Bird, J.E., Watson, C.A., Bostwick, J.S., Giancarli, M., Allegretto, N., Hua, J., Harden, D., and Guay, J. (2017). Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Sci. Transl. Med., 9.","DOI":"10.1126\/scitranslmed.aaf5294"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/ATVBAHA.117.310104","article-title":"PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation","volume":"38","author":"Wilson","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/17512433.2019.1607293","article-title":"Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura","volume":"12","author":"Tersteeg","year":"2019","journal-title":"Expert Rev. Clin. Pharm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of acute coronary syndromes and their implications for therapy","volume":"368","author":"Libby","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCINTERVENTIONS.109.884478","article-title":"Anticoagulant therapy for percutaneous coronary intervention","volume":"3","author":"Rao","year":"2010","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/eurheartj\/ehn008","article-title":"Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: Insights from the STEEPLE trial","volume":"29","author":"Montalescot","year":"2008","journal-title":"Eur. Heart J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1055\/s-0038-1657768","article-title":"Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study)","volume":"118","author":"Sumaya","year":"2018","journal-title":"Thromb. Haemost."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","article-title":"Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: The international randomised open-label ATOLL trial","volume":"378","author":"Montalescot","year":"2011","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehz059","article-title":"Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: A subgroup analysis from the RE-DUAL PCI trial","volume":"40","author":"Oldgren","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehr334","article-title":"RUBY-1: A randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome","volume":"32","author":"Steg","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1160\/TH13-07-0543","article-title":"Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome","volume":"111","author":"Goldstein","year":"2014","journal-title":"Thromb. Haemost."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1111\/jth.14595","article-title":"Nomenclature of factor XI and the contact system","volume":"17","author":"Schmaier","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0049-3848(16)30354-1","article-title":"The hemostatic role of factor XI","volume":"141","author":"Puy","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1084\/jem.20050664","article-title":"Defective thrombus formation in mice lacking coagulation factor XII","volume":"202","author":"Schuh","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1538-7836.2009.03393.x","article-title":"Factor XI deficiency in animal models","volume":"7","author":"Oschatz","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/CIRCRESAHA.118.313155","article-title":"Antithrombotic Agents","volume":"124","author":"Chan","year":"2019","journal-title":"Circ. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood-2008-01-136820","article-title":"The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis","volume":"112","author":"Buyue","year":"2008","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11886-010-0117-6","article-title":"Antithrombotic therapy in acute coronary syndrome: How far up the coagulation cascade will we go?","volume":"12","author":"Woodruff","year":"2010","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1084\/jem.20060217","article-title":"Are hemostasis and thrombosis two sides of the same coin?","volume":"203","author":"Colman","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1055\/s-0039-1692439","article-title":"The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials","volume":"45","author":"DeLoughery","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"245","DOI":"10.31083\/j.rcm.2019.04.56","article-title":"Factors IX, XI, and XII: Potential therapeutic targets for anticoagulant therapy in atherothrombosis","volume":"20","author":"Rai","year":"2019","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/13543776.2020.1705783","article-title":"Factor XI(a) inhibitors for thrombosis: An updated patent review (2016-present)","volume":"30","year":"2020","journal-title":"Expert Opin. Ther. Pat."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/7\/2059\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:45:12Z","timestamp":1760175912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/7\/2059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":96,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["jcm9072059"],"URL":"https:\/\/doi.org\/10.3390\/jcm9072059","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2020,6,30]]}}}